Tata Group to diversify into life sciences sector

Published: 12-Nov-2004

The Rs 65,000-crore Tata Group is drawing up a fresh strategy that will see it diversifying into life sciences including pharmaceuticals, biotechnology and Ayurveda with a thrust on r&d, manufacture and retail.


The Rs 65,000-crore Tata Group is drawing up a fresh strategy that will see it diversifying into life sciences including pharmaceuticals, biotechnology and Ayurveda with a thrust on r&d, manufacture and retail.

It is the first time that India's premier business group has set its sights on venturing into drug sector. Though the Group has yet to specify the basic areas of interest, it is likely that a significant investment will be made in r&d and in the setting up of manufacturing capabilities.

The international business plan of the Group is also being structured in such way that it would emerge as a major player in Asia, with particular emphasis on South Asian Association for Regional Cooperation (Saarc) countries.

  

You may also like